Hillenbrand (NYSE:HI) Q2 CY2025 Deep Dive: Portfolio Simplification, Tariff Headwinds, and Early Signs of Order Recovery

Industrial processing equipment and solutions provider Hillenbrand (NYSE:HI) reported Q2 CY2025 results exceeding the market’s revenue expectations, but sales fell by 23.9% year on year to $598.9 million. The company’s full-year revenue guidance of $2.61 billion at the midpoint came in 1.1% above analysts’ estimates. Its non-GAAP profit of $0.51 per share was 3% above analysts’ consensus estimates.

Is now the time to buy HI? Find out in our full research report (it’s free).

StockStory’s Take

Hillenbrand’s second quarter saw revenue ahead of Wall Street’s expectations, despite a substantial year-over-year decline. Management attributed the quarter’s results to continued cautious order behavior amid macroeconomic uncertainty and recent tariff announcements, especially in its Advanced Process Solutions segment. CEO Kimberly K. Ryan explained, “We continued to experience cautious order behavior from customers amid continued global macroeconomic uncertainty and tariff announcements,” emphasizing that project delays rather than cancellations were the primary issue. The company also completed portfolio simplification steps, including divesting its Milacron Injection Molding & Extrusion business and a minority stake in TerraSource, using proceeds to reduce debt.

Looking forward, Hillenbrand’s guidance is shaped by early signs of stabilizing order activity, especially as customers begin to navigate the new tariff landscape. Management believes the integration of Food, Health and Nutrition acquisitions, cost synergy realization, and an increased focus on cross-selling and systems solutions will drive commercial momentum. CFO Megan Walke noted, “The recent key order wins in late July provide us greater line of sight to achieve our full year expectations,” but cautioned that the pace of recovery is dependent on the timing of customer investment decisions and ongoing macroeconomic developments.

Key Insights from Management’s Remarks

Management highlighted that results were shaped by order timing delays tied to macro uncertainty and tariffs, balanced by meaningful cost synergies and portfolio actions.

• Portfolio simplification progress: Hillenbrand completed the divestiture of its Milacron Injection Molding & Extrusion business and sold its minority stake in TerraSource, generating over $380 million in proceeds, which were used to reduce debt and sharpen focus on higher-margin businesses.
• Cost synergy realization: Management achieved $30 million in run-rate cost synergies from the Linxis and FPM acquisitions within 20 months, well ahead of the original target, supporting margin performance despite lower volumes.
• Tariff and macro uncertainty: The company faced ongoing customer order delays due to uncertainty created by global tariffs and cautious macroeconomic conditions, particularly affecting large capital project orders in Advanced Process Solutions.
• Commercial integration initiatives: Cross-selling between legacy and acquired Food, Health and Nutrition brands has begun to show results, with management reporting $40 million in cross-sell sales to date, and continued focus on leveraging the global Coperion footprint for further growth.
• Localized supply chain response: To mitigate tariff impacts, Hillenbrand accelerated its “in-region, for-region” manufacturing strategy, localizing supply chains and shifting production to reduce exposure to trade disruptions.

Drivers of Future Performance

Hillenbrand’s outlook is anchored by anticipated stabilization in customer orders, ongoing cost synergies, and commercial integration initiatives, while remaining cautious about macro and tariff risks.

• Order recovery and backlog stabilization: Management expects a gradual normalization of customer order patterns as clients adapt to the tariff environment, with recent upticks in plastics-related orders providing early signs but not yet a consistent trend.
• Commercial synergies and cross-selling: The company is prioritizing commercial integration, aiming to increase cross-selling across its Food, Health and Nutrition brands and to leverage its global sales network, which management believes will drive incremental revenue growth.
• Margin management amid headwinds: Persistent inflation, competitive pricing pressures, and fixed cost deleverage remain risks, but management is focused on ongoing cost optimization and improved contract structures to protect profitability as order volumes recover.

Catalysts in Upcoming Quarters

Looking ahead, our analysts are watching (1) the pace and consistency of order recovery in Advanced Process Solutions as customers adapt to new tariff realities, (2) measurable progress in commercial integration and cross-selling within Food, Health and Nutrition, and (3) whether recent cost synergies and portfolio moves continue to support margin stability. The timing and magnitude of backlog growth will be a key marker for sustained recovery.

Hillenbrand currently trades at $23.26, up from $19.80 just before the earnings. Is there an opportunity in the stock?See for yourself in our full research report (it’s free).

Stocks That Trumped Tariffs

Donald Trump’s April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.

The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.